ScreenerHero

GUD Knight Therapeutics Inc.

TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · knighttx.com
10.36CAD+0.39%Mkt Cap: 741.14M $P/E: 69.07

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap741.14M USD
Enterprise Value674.99M USD
Revenue (TTM)398.58M USD
Gross Profit145.82M USD
Net Income (TTM)-3.91M USD
Revenue/Share5.53 CAD
Last Price10.36 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees830
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)69.07
P/E (Forward)39.69
PEG—
EV/EBITDA11.42
EV/Revenue1.69
P/S1.85
P/B1.27
EPS (TTM)0.15
EPS (Forward)0.26
52W Range
5.66091% of range10.80
52W High10.80 CAD
52W Low5.660 CAD
Profitability
Gross Margin44.49%
Oper. Margin6.21%
EBITDA Margin14.83%
Profit Margin-1.19%
ROE-0.70%
ROA-0.51%
Growth
Revenue Growth34.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF50.22M USD
CapEx (TTM)24.54M USD
FCF Margin11.58%
FCF Yield6.23%
Net Debt-63.28M USD
Net Debt/EBITDA-1.07
Balance Sheet
Debt/Equity0.10
Current Ratio2.28
Quick Ratio1.45
Book Value/Sh8.13 CAD
Cash/Share1.23 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.19 CAD
Upside (mean)+8.0%
Target Range10.80 CAD – 12.00 CAD
10.80+8.0% to mean12.00
# Analysts7
Ownership
Shares Out.98.23M
Float60.60M
Insiders46.02%
Institutions19.05%
Short Interest
Short Ratio15.4d
Short % Out.1.32%
Shares Short1.30M
Short (prev mo.)1.42M
Technical
SMA 509.838 (+5.3%)
SMA 2008.037 (+28.9%)
Beta0.04
S&P 52W Chg14.58%
Avg Vol (30d)82.18K
Avg Vol (10d)72.65K
Technical Indicators
RSI (14)58.3
MACD0.1938
MACD Signal0.1727
MACD Hist.+0.0212
BB Upper10.62 CAD
BB Middle10.14 CAD
BB Lower9.663 CAD
BB Width9.46%
ATR (14)0.2591 CAD
Vol Ratio (20d)0.69x